Clinical Application of Plasma Neurofilament Light Chain in a Memory Clinic: A Pilot Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose: Neurofilament light chain (NfL) has been considered as a biomarker for neurodegenerative diseases including Alzheimer’s disease (AD). We measured plasma NfL levels in older adults with cognitive complaints and evaluated their clinical usefulness in AD. Methods: Plasma levels of NfL, measured by using the single molecule array method, were acquired in a total of 113 subjects consisting of subjective cognitive decline (SCD; n=14), mild cognitive impairment (MCI; n=37), or dementia of Alzheimer type (DAT; n=62). Plasma NfL level was compared among three groups, and its association with cognitive and functional status was also analyzed. Results: After adjusting for age, plasma NfL level was higher in subjects with DAT (65.98±84.96 pg/mL), compared to in subjects with SCD (16.90±2.54 pg/mL) or MCI (25.53±10.42 pg/mL, p=0.004). NfL levels were correlated with scores of the mini-mental state examination (r=−0.242, p=0.021), clinical dementia rating (CDR) (r=0.291, p=0.005), or CDR-sum of boxes (r=0.276, p=0.008). Just for participants who performed amyloid positron emission tomography (PET), the levels were different between subjects with PET (−) (n=17, 25.95±13.25 pg/mL) and PET (+) (n=16, 63.65±81.90 pg/mL, p=0.010). Additionally, plasma NfL levels were different between vascular dementia and vascular MCI, and between Parkinson’s disease- dementia and no dementia. Conclusions: This pilot study shows that in subjects with DAT, plasma NfL levels increase. Plasma NfL level correlated with cognitive and functional status. Further longitudinal studies may help to apply the plasma NfL levels to AD, as a potential biomarker for the diagnosis and predicting progression.
Abstract
Background and Purpose: Neurofilament light chain (NfL) has been considered as a biomarker for neurodegenerative diseases including Alzheimer’s disease (AD). We measured plasma NfL levels in older adults with cognitive complaints and evaluated their clinical usefulness in AD. Methods: Plasma levels of NfL, measured by using the single molecule array method, were acquired in a total of 113 subjects consisting of subjective cognitive decline (SCD; n=14), mild cognitive impairment (MCI; n=37), or dementia of Alzheimer type (DAT; n=62). Plasma NfL level was compared among three groups, and its association with cognitive and functional status was also analyzed. Results: After adjusting for age, plasma NfL level was higher in subjects with DAT (65.98±84.96 pg/mL), compared to in subjects with SCD (16.90±2.54 pg/mL) or MCI (25.53±10.42 pg/mL, p=0.004). NfL levels were correlated with scores of the mini-mental state examination (r=−0.242, p=0.021), clinical dementia rating (CDR) (r=0.291, p=0.005), or CDR-sum of boxes (r=0.276, p=0.008). Just for participants who performed amyloid positron emission tomography (PET), the levels were different between subjects with PET (−) (n=17, 25.95±13.25 pg/mL) and PET (+) (n=16, 63.65±81.90 pg/mL, p=0.010). Additionally, plasma NfL levels were different between vascular dementia and vascular MCI, and between Parkinson’s disease- dementia and no dementia. Conclusions: This pilot study shows that in subjects with DAT, plasma NfL levels increase. Plasma NfL level correlated with cognitive and functional status. Further longitudinal studies may help to apply the plasma NfL levels to AD, as a potential biomarker for the diagnosis and predicting progression.
참고문헌 (54)
- Scheltens P, "Alzheimer’s disease", Lancet, 388, pp.505~517 (2016)
- Jack CR Jr, "Magnetic resonance imaging in Alzheimer’s Disease Neuroimaging Initiative 2", Alzheimers Dement, 11, pp.740~756 (2015)
- Laforce R Jr, "Molecular imaging in dementia : past, present, and future", Alzheimers Dement, 14, pp.1522~1552 (2018)
- Blennow K, "The past and the future of Alzheimer’s disease fluid biomarkers", J Alzheimers Dis, 62, pp.1125~1140 (2018)
- Teunissen CE, "Neurofilaments as biomarkers in multiple sclerosis", Mult Scler, 18, pp.552~556 (2012)
- Bacioglu M, "Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases", Neuron, 91, pp.56~66 (2016)
- Zetterberg H, "Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression", JAMA Neurol, 73, pp.60~67 (2016)
- Olsson B, "CSF and blood biomarkers for the diagnosis of Alzheimer’s disease : a systematic review and meta-analysis", Lancet Neurol, 15, pp.673~684 (2016)
- Petzold A, "A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia", Neurodegener Dis, 4, pp.185~194 (2007)
- Gaiottino J, "Increased neurofilament light chain blood levels in neurodegenerative neurological diseases", PLoS One, 8, pp.e75091~ (2013)
- Lewczuk P, "Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease", Alzheimers Res Ther, 10, pp.71~ (2018)
- Mattsson N, "Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease", JAMA Neurol, 74, pp.557~566 (2017)
- Lee EH, "Serum neurofilament light chain level as a predictor of cognitive stage transition", Alzheimers Res Ther, 14, pp.6~ (2022)
- Zhao Y, "Neurofilament light chain protein in neurodegenerative dementia : a systematic review and network meta-analysis", Neurosci Biobehav Rev, 102, pp.123~138 (2019)
- Forgrave LM, "The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis", Alzheimers Dement(Amst), 11, pp.730~743 (2019)
- Weston PS, "Serum neurofilament light in familial Alzheimer disease : a marker of early neurodegeneration", Neurology, 89, pp.2167~2175 (2017)
- McKhann G, "Clinical diagnosis of Alzheimer’s disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
- Morris JC, "The clinical dementia rating(CDR) : current version and scoring rules", Neurology, 43, pp.2412~2414 (1993)
- Folstein MF, "“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician", J Psychiatr Res, 12, pp.189~198 (1975)
- Petersen RC, "Mild cognitive impairment : clinical characterization and outcome", Arch Neurol, 56, pp.303~308 (1999)
- Winblad B, "Mild cognitive impairment--beyond controversies, towards a consensus : report of the International Working Group on Mild Cognitive Impairment", J Intern Med, 256, pp.240~246 (2004)
- Abdulrab K, "Subjective memory impairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria", Eur Psychiatry, 23, pp.321~330 (2008)
- Stewart R, "Subjective cognitive impairment", Curr Opin Psychiatry, 25, pp.445~450 (2012)
- Román GC, "Vascular dementia:diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop", Neurology, 43, pp.250~260 (1993)
- Stephan BC, "Beyond mild cognitive impairment : vascular cognitive impairment, no dementia(VCIND)", Alzheimers Res Ther, 1, pp.4~ (2009)
- Gibb WR, "The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease", J Neurol Neurosurg Psychiatry, 51, pp.745~752 (1988)
- Emre M, "Clinical diagnostic criteria for dementia associated with Parkinson’s disease", Mov Disord, 22, pp.1689~1707 (2007)
- Shim YS, "Effects of medial temporal atrophy and white matter hyperintensities on the cognitive functions in patients with Alzheimer’s disease", Eur Neurol, 66, pp.75~82 (2011)
- Fazekas F, "MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging", AJR Am J Roentgenol, 149, pp.351~356 (1987)
- Scheltens P, "Atrophy of medial temporal lobes on MRI in"probable"Alzheimer’s disease and normal ageing : diagnostic value and neuropsychological correlates", J Neurol Neurosurg Psychiatry, 55, pp.967~972 (1992)
- Erkinjuntti T, "Subcortical ischemic vascular disease and dementia", Int Psychogeriatr, 15(Suppl 1), pp.23~26 (2003)
- Zhou W, "Plasma neurofilament light chain levels in Alzheimer’s disease", Neurosci Lett, 650, pp.60~64 (2017)
- Lycke JN, "Neurofilament protein in cerebrospinal fluid : a potential marker of activity in multiple sclerosis", J Neurol Neurosurg Psychiatry, 64, pp.402~404 (1998)
- Zanier ER, "Neurofilament light chain levels in ventricular cerebrospinal fluid after acute aneurysmal subarachnoid haemorrhage", J Neurol Neurosurg Psychiatry, 82, pp.157~159 (2011)
- Zetterberg H, "Neurochemical aftermath of amateur boxing", Arch Neurol, 63, pp.1277~1280 (2006)
- Kuhle J, "Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity", Mult Scler, 22, pp.1550~1559 (2016)
- Rohrer JD, "Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia", Neurology, 87, pp.1329~1336 (2016)
- Kuhle J, "Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome", J Neurol Neurosurg Psychiatry, 86, pp.273~279 (2015)
- Kuhle J, "Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples : ELISA, electrochemiluminescence immunoassay and Simoa", Clin Chem Lab Med, 54, pp.1655~1661 (2016)
- Steinacker P, "Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias", Neurology, 88, pp.961~969 (2017)
- Gisslén M, "Plasma concentration of the neurofilament light protein(NFL)is a biomarker of CNS injury in HIV infection : a cross-sectional study", EBioMedicine, 3, pp.135~140 (2015)
- Hansson O, "Blood-based NfL : a biomarker for differential diagnosis of parkinsonian disorder", Neurology, 88, pp.930~937 (2017)
- Lin YS, "Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease", Sci Rep, 8, pp.17368~ (2018)
- Mattsson N, "CSF biomarkers in neurodegenerative diseases", Clin Chem Lab Med, 49, pp.345~352 (2011)
- Xu Y, "Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson’s disease", J Neurol, 263, pp.1178~1187 (2016)
- Lee SH, "Brain volumetry in Parkinson’s disease with and without dementia : where are the differences", Acta Radiol, 54, pp.581~586 (2013)
- Ogata J, "Vascular dementia : the role of changes in the vessels", Alzheimer Dis Assoc Disord, 13(Suppl 3), pp.S55~S58 (1999)
- Pantoni L, "Pathophysiology of age-related cerebral white matter changes", Cerebrovasc Dis, 13(Suppl 2), pp.7~10 (2002)
- Wallin A, "The overlap between Alzheimer’s disease and vascular dementia : the role of white matter changes", Dement Geriatr Cogn Disord, 9(Suppl 1), pp.30~35 (1998)
- Mattsson N, "Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease", JAMA Neurol, 74, pp.557~566 (2017)
- Weston PS, "Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease", Alzheimers Res Ther, 11, pp.19~ (2019)
- Jin M, "Role of neurofilament light chain as a potential biomarker for Alzheimer’s disease : a correlative meta-analysis", Front Aging Neurosci, 11, pp.254~ (2019)
- Bos I, "Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer’s disease spectrum", Alzheimers Dement, 15, pp.644~654 (2019)
- Hall JR, "Relationship of neurofilament light(NfL)and cognitive performance in a sample of Mexican Americans with normal cognition, mild cognitive impairment and dementia", Curr Alzheimer Res, 17, pp.1214~1220 (2020)